SAHAREK JOHN P. 4
4 · HARROW, INC. · Filed Sep 13, 2024
Insider Transaction Report
Form 4
HARROW, INC.HROW
SAHAREK JOHN P.
CEO & President, ImprimisRx
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-09-11−90,000→ 0 totalExercise: $7.37Exp: 2025-02-01→ Common Stock (90,000 underlying) - Exercise/Conversion
Common stock
2024-09-11$7.37/sh+90,000$663,300→ 344,803 total - Tax Payment
Common stock
2024-09-11$41.37/sh−45,140$1,867,442→ 299,663 total
Footnotes (1)
- [F1]The stock option was granted on February 1, 2015 under the Issuers 2007 Stock Incentive and Awards Plan and the shares subject to the stock option became exercisable over a 3 year period following its grant date. The stock option had an expiration date of February 1, 2025. 29,107 shares of Harrow common stock listed as disposed were withheld from issuance by Harrow to satisfy Mr. Saharek's payroll tax liability incident and 16,033 shares of Harrow common stock listed as disposed were withheld from issuance by Harrow to satisfy Mr. Saharek's cost to purchase the stock option.